---
layout: post
title: "Drug Products, Including Biological Products, That Contain Nanomaterials; Guidance for Industry; Availability"
date: 2026-02-05 18:58:55 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-08572
original_published: 2022-04-22 00:00:00 +0000
significance: 8.00
---

# Drug Products, Including Biological Products, That Contain Nanomaterials; Guidance for Industry; Availability

**Published:** February 05, 2026 18:58 UTC
**Source:** Federal Register
**Original Published:** April 22, 2022 00:00 UTC
**Document Number:** 2022-08572

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Drug Products, Including Biological Products, That Contain Nanomaterials." This guidance finalizes the draft guidance issued December 18, 2017, developed to provide industry with the Agency's current thinking for the development of human drug products, including those that are biological products, in which a nanomaterial is present in the finished dosage form. The guidance also includes recommendations for applicants and sponsors of investigational, premarket, and postmarket submissions for these products.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/04/22/2022-08572/drug-products-including-biological-products-that-contain-nanomaterials-guidance-for-industry)
- API: https://www.federalregister.gov/api/v1/documents/2022-08572

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
